← Eichor
Study identifier: NCT06908746 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy and Safety of Citrate Anticoagulation in CRRT for Patients With Liver Failure/DysfuncTION, the CAUTION Trial! A Retrospective Study on Etiology of Liver Failure and Their Complications

Condition: Liver Failure · AKI - Acute Kidney Injury  ·  Sponsor: University Hospital, Antwerp

PhaseN/A
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Study design A retrospective cohort study will be conducted to compare the efficacy and safety of citrate anticoagulation in CRRT among patients with liver failure/dysfunction and severe shock. Objectives 1. Primary Objective: To determine if the etiology of liver failure impacts the incidence of citrate-related complications in patients undergoing CRRT. 2. Secondary Objectives: To compare the efficacy of citrate anticoagulation in terms of renal recovery, filter lifespan, and patient survival between those with liver failure/dysfunction and severe shock.

This description comes directly from the study's public registry record.

Talk to the study team

Rita Jacobs, Dr.  ·  +32 3 821 36 35  ·  rita.jacobs2@uza.be

Petra Vertongen  ·  +32 3 8214404  ·  studies.inzo@uza.be

Always discuss trial participation with your own doctor first.

Locations (1)

Antwerp University HospitalEdegem, Antwerp, BelgiumRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06908746